Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
口服布鲁顿酪氨酸激酶抑制剂利扎替尼治疗免疫性血小板减少症患者的疗效和安全性结果:II期B部分研究
期刊:American Journal of Hematology
影响因子:9.9
doi:10.1002/ajh.27539
Cooper, Nichola; Jansen, A J Gerard; Bird, Robert; Mayer, Jiří; Sholzberg, Michelle; Tarantino, Michael D; Garg, Mamta; Ypma, Paula F; McDonald, Vickie; Percy, Charles; Košťál, Milan; Goncalves, Isaac; Bogdanov, Lachezar H; Gernsheimer, Terry B; Diab, Remco; Yao, Mengjie; Daak, Ahmed; Kuter, David J